We found that inhibition of MEK1/2 had a modest impact on the survival of AKras+/G12D mice, based upon endpoint defined by onset of clinical signs associated with tumour burden, but significantly extended survival in AKrasfl/G12D mice (median survival extended from 26 days to 115 days) (Fig. 4c). Here, MAP2K1 is linked to neoplasm.